32 C
New York
Saturday, June 6, 2026

Tag: drugs

Instinct Science Named to the 2025 Inc. 5000 List of Fastest-Growing Private Companies

PHILADELPHIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Instinct Science, a leading innovator in veterinary workflow, decision support, education, and practice management software, has been named to the Inc. 5000 list of the fastest-growing private companies in America, earning the #388 spot overall, ranking #6 in Pennsylvania, and #37 in Software companies nationwide.

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Psychedelic Drugs Market Research Report 2025-2033 | Rising Demand for Non-Hallucinogenic Psychedelics Expands Patient Base, Breakthrough Regulatory Designations Accelerate Approvals

Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.
Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market

Saudi Arabia Generic Drugs Market Outlook Report 2025-2033 | Government Cost-Cutting, Local Manufacturing, and Public Awareness Fuel Rapid Growth

The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.
The Saudi Arabia Generic Drugs Market is projected to expand from US$ 4.05 billion in 2024 to US$ 8.11 billion by 2033, registering a CAGR of 8.02%. This growth is driven by increased healthcare needs, government initiatives to reduce pharmaceutical spending, and rising awareness of affordable alternatives. Supportive regulatory policies by the Saudi Food and Drug Authority (SFDA) and investments in local manufacturing are further spurring market expansion. The market is also bolstered by growing demand due to the rising prevalence of chronic diseases and increased acceptance among consumers and healthcare professionals.

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

DRI Healthcare Reports Second Quarter 2025 Results

Subsequent to the end of the quarter, completed the previously announced transaction to internalize its investment management functionPortfolio assets generate Total Income of $44.1...

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products.  MediPharm...

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000...

NEW YORK and NEW ORLEANS, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

-         The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrugs